IJMPR 2025, 9(3), 48-56

International Journal of Modern Pharmaceutical Research
www.ijmpronline.com

ISSN: 2319-5878
IJMPR
Review Article
SJIF Impact Factor: 6.669

ANTI-PSYCHOTICS SAFETY IN HEPATIC DISEASE

***Dr. Pooja Boban**

MBBS, General Practitioner, India.

Article Received on: 03/01/2025
Article Revised on: 23/01/2025
Article Accepted on: 12/02/2025

***Corresponding Author**
Dr. Pooja Boban
MBBS, General Practitioner, India.

ABSTRACT
In order to compare the risk and kinds of liver injury associated with antipsychotic medication, clinicians treating psychiatric problems in medically unwell patients require a comprehensive resource. There is a reciprocal association between general medical diseases and mental health illnesses. Concurrent medical conditions are more common in patients with severe mental illness, and mental illness is more likely to develop in those with chronic medical disorders. Psychotropic medications are frequently used to treat mental illnesses in people who are medically unwell. When prescription psychiatric medications, comorbid medical conditions present numerous difficulties. Psychotropic medications that prevent or barely undergo hepatic metabolism are better for people with liver disease. Since there may not be enough safety data, care must be taken when providing any psychiatric medication to patients with severe liver illness. Preferring hepatic metabolism escaping drug may prevent further damage to liver.

KEYWORDS: Antipsychotics, safety, Hepatic, Disease, Metabolism.

INTRODUCTION

Liver is the main organ where drugs, such as antidepressants (ADs) and antipsychotics (APs), are metabolized, it is crucial to understand how a particular drug and its metabolites impact the structure and function of the liver. Hepatotoxicity can lead to cirrhosis (disruption of the normal architecture of the liver), fibrosis (excessive accumulation of extracellular matrix proteins), steatohepatitis (steatosis with inflammation), and hepatic steatosis (fat accumulation in the liver).[1] When significant portions of the liver sustain irreparable damage and lose their ability to function, liver failure results. In Western nations, drug-induced liver injury (DILI) ranks as the fourth leading cause of liver disease.[2] Between 1/10000 and 1/100000 patients-years have DILI.[3,4]

After anti-infectious medications, the second most significant class of pharmaceuticals linked to hepatotoxicity are those used in neurology and psychiatry.[5] Patients with cirrhosis or chronic hepatic failure have a lower hepatic reserve, and DILI may be more severe in these patients.[6] As a result, high-risk medications ought to be avoided in people who already have liver disease.[7]

End-stage liver disease patients may experience psychiatric symptoms as a result of co-occurring psychological or physiological processes (e.g., liver failure, encephalopathy, adjustment reactions to the stress of severe physical sickness, etc.). It is necessary to treat all of these conditions with psychotropic medications in addition to psychological therapies. Because they are medically sensitive and more likely to experience adverse drug reactions, individuals with end-stage liver disease in these situations need extra attention.[8]

Pathogenesis and pathological changes of drug-induced liver injury

Direct hepatotoxicity and idiosyncratic hepatotoxicity reactions to medicines are two ways to summarize the complicated pathophysiology of DILI. Drugs and their metabolites induce the upstream events in the process, while imbalances in the hepatic target cell damage and protective pathways generate the downstream events. Direct hepatotoxicity, also known as intrinsic DILI, is the term used to describe medications that are consumed into the body and/or the direct harm that their metabolites do to the liver. It is frequently dose-dependent and typically predictable. Drugs that directly harm the liver can also cause secondary liver injury mechanisms, like inflammation and immunology.[9] In recent years, research on the pathophysiology of idiosyncratic hepatotoxicity has been very popular.

Human leukocyte antigen systems (HLA), transmembrane transporters, solute transport proteins, and drug-metabolizing enzymes all have gene polymorphisms that can easily trigger adaptive immune responses to certain medications, making the host more vulnerable to DILI. Through a number of molecular pathways, hepatocyte damage and death can result from oxidative stress and hepatic mitochondrial damage brought on by medications and active metabolites. The progression of DILI was aided by the persistent and excessive endoplasmic reticulum stress response (ERSR), which disrupted the unfolded protein response's

(UPR) stress-reduction impact. Various death signaling pathways can be activated by drugs and their metabolites, which can lead to autophagic cell death and necrosis of cells. The final frequent occurrence of DILI may be an adaptive immune attack.[9,10]

With the exception of sulpiride, amisulpride, risperidone, and paliperidone, the majority of antipsychotic medications are metabolized by the cytochrome P450 (CYP) system. Most antipsychotic medications mostly metabolize via CYP2D6 and CYP3A4, whereas some (such clozapine and olanzapine) metabolize via CYP1A2.[11]

The liver damage brought on by antipsychotic medications may be caused by three primary mechanisms:

- First, cholestasis, which may be linked to immune-mediated hypersensitivity, can be caused by phenothiazines (particularly chlorpromazine) or their metabolites altering bile secretion and excretion.[12]
- Second, hepatocytes are attacked by the direct toxic effects of the medicines or their metabolites; a slow build-up of tiny poisonous metabolites results in the delayed toxic effect.[12] Hepatocytes can adjust to this alteration by up-regulating antioxidant genes or chaperone proteins, even though the medication still damages them.[13]
- Third, by raising the risk of metabolic syndrome, antipsychotic medications indirectly impact the liver by raising the risk of non-alcoholic fatty liver disease.[14]

Compared to other new antipsychotic medications, clozapine and olanzapine have been shown in some studies to raise the risk of non-alcoholic fatty liver disease[15] (Olanzapine OR 18.6; 95% CI 2.8-68.4; clozapine OR 34.6; 95% CI 2.8-824.9) and two case reports of acute liver injury following clozapine use. The asymptomatic rise of aminotransferase caused by clozapine, olanzapine, quetiapine, and risperidone was 40%, 30%, 27%, and 31%, respectively.[16,17] It usually occurs during the first few days to weeks of taking the drug. Hepatic cells, bile duct epithelial cells, and vascular endothelial cells in the hepatic sinusoid and hepatic vein systems are the primary targets of DILI. Nearly every area of liver pathological alterations is covered by the many and intricate damage modalities.[18]

Acute cellular lysis is the predominant pathogenic alteration brought on by antipsychotics.[19] Phenothiazine is one example of the hepatotoxicity caused by traditional antipsychotic medications. In particular, acute cholestasis is a symptom of liver damage brought on by chlorpromazine. The new antipsychotics have a variety of liver damage mechanisms. According to studies[19], clozapine can result in eosinophil infiltration, cholestatic hepatitis with necrosis of a single hepatocyte, and acute necrotic hepatitis; risperidone typically causes cholestatic hepatitis and infrequent allergy symptoms; The primary source of hepatocyte damage, widespread hepatocyte necrosis, and nonspecific inflammatory infiltration is quetiapine; olanzapine causes hepatocyte destruction, accompanying monocytes, centrolobular necrosis of lymphocytes, and eosinophil infiltration in the portal area; Ziprasidone typically results in systemic, eosinophilic, hypersensitive, and hepatocyte damage symptoms. drug-induced response syndrome; there are no pertinent reports for amisulpride, aripiprazole, paliperidone, or aripiprazole.

Sydney A Lefay (2023)[20] did a narrative review, in her study Liver impairment caused by antipsychotics is rare to uncommon, according to the evidence. The drugs that are most likely to cause hepatotoxicity are chlorpromazine, clozapine, and olanzapine; quetiapine and risperidone are moderately risky; and haloperidol is regarded as low to moderately risky. Lower-risk medications that have not been linked to liver failure include loxapine, lurasidone, paliperidone, and aripiprazole. The most frequent liver injury caused by antipsychotics is mild, self-limiting transaminitis, which is followed by hepatocellular disease, steatosis, and mixed liver injury. In cases of severe liver illness, the decision to stop taking the antipsychotic should be made after a thorough risk-benefit analysis. When the advantages of treating psychosis outweigh the dangers, dose modifications and close observation are advised for mild to moderate cases. When starting therapy with a higher-risk antipsychotic, patients without pre-existing liver illness should be advised to report any liver injury symptoms and undergo routine laboratory testing.

Prevalence of liver disease in psychiatric disorders

A growing body of research indicates that mental populations have a greater prevalence of hepatitis B and C than the general population. In a recent meta-analysis, the authors revealed pooled prevalence rates of hepatitis C ranging from 3.0% in South America to 17.4% in North America, whereas the pooled prevalence of hepatitis B in severe mental illness varied from 2.2% in South America to 9.7% in Asia.[21]

More precisely, research using population-based cohorts have demonstrated that the prevalence of CLD was higher in individuals with schizophrenia (7.0%) than in the general population (6.1%).[21] The prevalence of CLD in bipolar disorder was 13.9%, which was 2.7 times greater than the 5.8% prevalence in the general population.[23] Additionally, the prevalence of hepatic sickness in bipolar disorder was 11% in the past and 17% in the present.[24]

Patients with CLD have also been observed to have higher incidences of anxiety disorders.[25] In addition, anxiety has a negative correlation with this group's health-related quality of life. A significant prevalence and morbidity of depression in non-alcoholic fatty liver disease (NAFLD) have been reported in a number of community-based studies. For example, a small case-

control study[27] revealed that the odds of lifetime depression were 3.8 times higher for patients with nonalcoholic steato-hepatitis than for controls without liver disease, and a population-based study found that 23.6% of CLD patients met the criteria for a diagnosis of depression.[26]

Clinical manifestations of antipsychotics drug induced hepatic failure

Acute liver illness, fulminant liver failure, and asymptomatic laboratory abnormalities are just a few of the clinical symptoms of drug-induced liver damage (DILI).[28] Over the past 20 years, a lot of attention has been paid to the hepatotoxicity of different Aps (anti-psychotics). However, the burden of DILI has been significantly understated since clinical trials are not always able to detect such uncommon occurrences.[29] 18% of the 462 medical items that were taken off the market between 1953 and 2013 were withdrawn because of their hepatotoxicity, according to a systematic review of those products.[30] It is widely acknowledged that the incidence rate of DILI is rising annually, which is a serious public health problem.[31]

According to recent researches, liver enzyme abnormalities were observed in both typical and AAPs (atypical anti-psychotics).[32–34] Serum bilirubin levels and liver enzymes have frequently been seen to rise asymptomatically as a result of AAPs.[16] Serious hepatotoxicity brought on by these medications has, however, hardly ever been documented.[35] Numerous cases of chlorpromazine-induced DILI often manifest as acute cholestatic hepatitis, and the hepatotoxicity caused by conventional APs has been documented in the literature.[3] On the other hand, AAPs are rarely associated with clinically substantial liver impairment with jaundice, but they frequently result in abnormalities in liver enzymes.[36] It is uncertain how common aberrant liver function is in people on AAPs. In cross-sectional or cohort studies with small sample sizes, it was challenging to thoroughly and methodically examine the relationship between APs and liver function.

Laboratory tests and examinations of DILI

The majority of laboratory tests revealed an asymptomatic increase in aminotransferase. When alanine aminotransferase (ALT) is three times higher than the normal limit, alkaline phosphatase (ALP) is two times higher than the usual value, or TB (total bilirubin) is greater than two milligrams per deciliter, it is considered a nonspecific liver injury and a relatively sensitive biomarker of liver injury. Thus, bilirubin excretion abnormalities and enzymatic changes were the primary findings of the laboratory examination, and there was a significant correlation between bilirubin and liver enzymology.[37] Furthermore, the majority of patients' blood routines did not significantly alter from the baseline time. Eosinophilia (>5%) may be seen in patients with allergy diathesis, and consideration should be given to how underlying illnesses may affect blood routine.

The main laboratory sign for identifying liver damage and diagnosing DILI, aside from ALT, AST, and ALP, is a change in TBil. Serum GGT's diagnostic sensitivity and specificity for cholestatic/mixed DILI must be lower than that of ALP. Severe liver injury is suggested by elevated serum TBil, decreased albumin levels, and a decline in blood coagulation function. The decline in blood coagulation function is often assessed using the prothrombin time international normalized ratio (INR) $\geq$ 1.5. Liver ultrasounds in patients with acute DILI revealed either modest edema or no discernible alterations. Drug-induced ALF patients may experience a decrease in hepatic volume.[37]

Imaging signs of cirrhosis, splenomegaly, and expansion of the portal vein diameter may be seen in a small percentage of individuals with persistent DILI. There is typically no discernible dilation of the intrahepatic and extrahepatic bile ducts. The majority of the recent research on serum, biochemistry, and histology indicators was connected to DILI, although none of them had specificity.[37]

Hepatic metabolism of psychotropic drugs

Psychotropic drug metabolism mostly takes place in the liver, where the most significant drug-metabolizing enzymes are members of the cytochrome P450-dependent monooxygenase (CYP) family of isoforms. A subfamily of heme-containing mono-oxidases known as CYP450 is responsible for the metabolism of vitamins, fatty acids, steroids, and xenobiotics (Furge and Guengerich 2006).[38] According to Zanger and Schwab (2013), CYPs 3A4, 2C9, 2C8, 2E1, and 1A2 are the isoforms that are most highly expressed in the liver, whereas CYPs 2A6, 2D6, 2B6, 2C19, and 3A5 are less common but still strongly expressed in the liver compared to other organs.[39] It has been noted that medications that are CYP450 enzyme substrates are more likely to cause DILI in a dose-independent way, whereas medications that are CYP450 inhibitors are more likely to cause DILI only when used at high daily doses.

It has been noted that medications that are CYP450 enzyme substrates are more likely to cause DILI in a dose-independent way, whereas medications that are CYP450 inhibitors are more likely to cause DILI only when used at high daily doses (Yu et al. 2014).[40] It has been demonstrated that some APs and ADs are inhibitors of CYP450 superfamily isoenzymes, but the majority are substrates of these enzymes. Age, sex, cytokines, hormones, xenobiotics, and genetic polymorphisms all affect CYP450 expression. More than half of all clinically used medications are metabolized by CYP3A4, which is widely expressed in the liver of most people (Zanger and Schwab 2013).[39]

Most ADs and APs are metabolized by the enzymes CYPs 3A4, 1A2, 2C9, 2C19, and 2D6. One of the possible causes of ADs' substantial liver metabolism and first-pass impact, which results in a varied bioavailability ranging from 30 to 80%, is their lipophilic nature, which allows them to pass through cell membranes. With the exception of paroxetine and fluvoxamine, which have a time range of 1 to 12 hours before reaching peak plasma concentration, the majority of ADs exhibit a linear relationship between dose and plasma concentrations (Mauri et al. 2014).[41]

Regarding APs, pharmacokinetic variations caused by age, modifications in the first-pass action, and the stimulation or inhibition of the metabolic system are the primary causes of the significant variation in the connection between dose and effect of various medications among patients (Mauri et al. 2018).[42] Additionally, the majority of APs are lipophilic, meaning they may freely pass through lipoidal membranes. Oral administration of APs results in significant pre-systemic clearance and good absorption (bioavailability: 10–70%). They are widely dispersed and have a high affinity for tissues and plasma proteins (75–99%) (Javaid 1994).[43]

Co-medication, however, may have an impact on pharmacokinetics. Patients who take numerous drugs and have multiple comorbidities are at risk for drug interactions. There are two types of drug interactions: pharmacokinetic and pharmacodynamic. Pharmacodynamic drug interactions imply that the nature, severity, or duration of the side effects or mechanisms of action of two medications taken concurrently are changed. Drug interactions known as pharmacokinetics happen when one medication changes how another is absorbed, distributed, metabolized, or eliminated (Preskorn and Werder 2006).[44] Drug-induced alterations in hepatic metabolism are the main cause of significant pharmacokinetic interactions with ADs and APs.

Medications that block or activate the proper CYP enzymes' metabolizing pathways can change the pharmacokinetics of these medications. Additionally, some ADs and APs can raise the levels of other drugs since they are inhibitors of specific CYP enzymes (Bleakley 2016).[45] When used with another medication that is a CYP450 substrate, psychotropic medications that function as CYP450 inhibitors may result in unfavorable drug interactions.

In certain situations, metabolites can be more reactive than the parent drug (bioactivation), despite the fact that drug metabolism typically produces an inactive metabolite (detoxication) (Park et al. 2011).[8] This is true for certain APs such risperidone and chlorpromazine, as well as tricyclic antidepressants (TCAs) like imipramine and amitriptyline (Telles-Correia et al. 2017).

Proteins, lipids, and nucleic acids within cells can be covalently bound by reactive metabolites, disrupting cell structure and function. One of the respiration mediators, the superoxide radical anion ($O2\cdot-$), can leak out of mitochondria when it binds to mitochondrial proteins. $O2\cdot-$, hydrogen peroxide (H2O2), hydroxyl radical (.OH), hydroperoxyl radical (HOO.), and singlet oxygen (1O2) are among the reactive oxygen species (ROS) that can be produced by CYP-mediated processes during drug metabolism in addition to reactive metabolites (Hrycay and Bandiera 2015).[46]

Antidepressants in liver disease

Selective serotonin reuptake inhibitors

It is generally accepted that this class of antidepressants is safe to use in CLD. However, in uncontrolled observations, sertraline has been linked to deadly liver damage. fluoxetine, paroxetine, citalopram, and escitalopram are examples of selective serotonin reuptake inhibitors (SSRIs) that have a lower risk of liver damage. GI bleeding and the degree of bleeding risk in individuals with liver illness are two issues with the use of SSRIs in these patients. Positively, findings from published reviews indicate that SSRIs in liver illness only raise the risk of bleeding events when they are co-prescribed with antiplatelet medications; this is in line with guidelines for standard practice.[47]

The half-life is extended and medication clearance is decreased due to typical pharmacokinetic alterations observed in CLD. It is typically advised to maintain the maintenance dosage at half of what healthy people take. On the other hand, the initial doses don't require any adjustments.

SSRIs have been shown to be effective in treating depressive symptoms in patients with chronic hepatitis C infection. Patients with IFN-induced depression showed improved depression scores were given paroxetine at a dose of 20 mg per day for four weeks. Similarly, citalopram (20 mg daily) was administered separately from a placebo at 2 and 4 weeks in a randomized controlled experiment evaluating the effectiveness of citalopram against placebo in IFN-induced depression. Additionally, therapeutic open-label trials of SSRIs in patients with hepatitis C did not reveal any significant side effects.[47]

SSRIs and Liver Injury

Drug-induced liver damage (DILI) can be broadly classified into subtypes according to the pathophysiological mechanism or pattern of liver injury. Hepatocellular, cholestatic, and mixed liver damage are the three primary types that have been identified. These subtypes are differentiated by the pattern of liver enzyme elevation; for example, cholestatic liver injury exhibits a pattern of elevated serum ALP titres with minimal elevation in ALT, hepatocellular injury is linked to elevated serum alanine aminotransferase (ALT) levels with little to no increase in ALP, and mixed liver injury

has both ALP and ALT titres that are pathologically high.

Liver injury can be classified as either intrinsic (dose dependent and based on drug accumulation) or idiosyncratic (more prevalent and dose independent) based on pathophysiology. The three types of idiosyncratic liver injury are immune-mediated, allergic, and metabolic. The former has a short latency period (1–6 weeks) and a hypersensitivity reaction with fever, rash, and eosinophilia, while the latter has a longer latency period (1 month–1 year) and no hypersensitivity reaction.

Serotonin norepinephrine reuptake inhibitors

In uncontrolled observations, duloxetine and venlafaxine have been linked to severe DILI. Duloxetine has been linked to all three forms of DILI (hepatocellular, cholestatic, and mixed), whereas venlafaxine has been linked to hepatocellular and cholestatic liver injury. Both of these agents have been linked to immune allergic and metabolic processes.[47]

Tricyclic Antidepressants (TCAs)

These medications are well known for their arrhythmogenic effects, CNS effects (such as drowsiness and seizures), orthostatic hypotension, and anticholinergic side effects (such as dry mouth, constipation, and urine retention). In individuals with CLD, clearance of these agents is typically decreased. Therefore, there can be a higher chance of side effects at the usual dosage; for instance, amitriptyline has been demonstrated to have more sedative effects in patients with liver cirrhosis. Other TCAs such imipramine, clomipramine, and nortriptyline have less information on their safety; however, there are also few cases of DILI linked to some of these medications. Patients with hepatic encephalopathy should be prescribed TCAs with caution because of the increased risk of sedation and sensorium deterioration.[47]

Monoamine oxidase inhibitors

The first monoamine oxidase inhibitor (MAOI) to be created, iproniazid, was taken off the market in the late 1970s when reports of severe DILI, even in people who appeared to be in good health, surfaced. Mortality rates were significant (up to 20%), and the majority of these occurrences happened during the first three months of treatment. Although research conducted on cirrhotic individuals has demonstrated extended half-lives and systemic clearance for tranylcypromine and moclobemide, nothing is known about the metabolism of other MAOIs in liver disease. The reversible MAOI moclobemide may be chosen over the irreversible MAOIs because of the lower risk of DILI, even though the majority of authorities discourage the use of MAOIs in liver disease.

Other anti-depressants

In patients with CLD, the pharmacokinetics of medications like bupropion and reboxetine are probably going to change. Bupropion in particular has been associated with negative side effects such nausea, vomiting, and seizures; therefore, patients with hepatic encephalopathy should use it with caution. Similarly, trazodone is also linked to sedation, therefore a comparable level of caution is necessary. At standard therapeutic dosages, DILI with trazodone has been documented.[48] Rarely, mirtazapine has also been linked to DILI caused by persistent jaundice. Additionally, when mirtazapine is taken with other serotonergic medications (such as SSRIs or serotonin norepinephrine reuptake inhibitors [SNRIs]), serotonin syndrome has been reported.

Use anti-depressants in liver transplant patients

The lack of controlled data on antidepressant usage among organ transplant patients suggests a gap in the research that makes it impossible to make definitive judgments. This group's concerns concerning antidepressant use are less about potential variations in pharmacokinetic profiles observed in CLD patients and more about safety, side effects, and potential medication interactions with immunosuppressive drugs.

Liver transplant recipients prefer SSRIs and SNRIs over MAOIs and TCAs because of their favorable side effect profile. Drug interactions are a problem, too, as paroxetine and fluoxetine block the cytochrome P450 3A4 enzymes that are necessary for the digestion of immunosuppressive drugs such tacrolimus and cyclosporine. As a result, when these SSRIs are taken together, there may be an increase in the systemic levels of these drugs.

SNRIs like venlafaxine and other SSRIs like sertraline and escitalopram have negligible effects on cytochrome P450 enzymes that are unlikely to be clinically significant. However, it is recommended that transplant recipients be closely monitored for tolerability issues due to the conflicting evidence regarding the effects of SSRIs on serum levels of cyclosporine. Interestingly, use of high-dose corticosteroids has been linked to worse mental health outcomes in post-liver transplant recipients; hence, efforts must be made to minimize the use of corticosteroids among depressed graft recipients.

First generation anti-psychotics

Steatosis development has often been linked to neuroleptic personalities. Both butyrophenones (like haloperidol) and phenothiazines (like chlorpromazine) have been linked to increased liver enzymes and infrequently, hepatocellular failure; in both situations, the lesion type is cholestatic and connected to immuno-allergic mechanisms. Compared to butyrophenones, phenothiazines have been linked to liver injury more often than the other agent. The usage of first-generation

antipsychotics (FGAs) has been linked to a significant case series of severe DILI.[49,50]

Second generation anti-psychotics

When it comes to liver disease, these medicines are generally safer than FGAs. However, using second-generation antipsychotics (SGA) can cause metabolic syndrome, which can thereafter result in non-alcoholic fatty liver disease. Using these medications may potentially result in asymptomatic increases in bilirubin and hepatic transaminases. Therefore, getting baseline liver function tests before starting SGAs and then monitoring at regular intervals (every year) is a smart idea. More frequent monitoring may be necessary for patients using clozapine and those who regularly use alcohol or other drugs.

Antipsychotics should generally be stopped if hepatic transaminases are elevated symptomatically or if the usual upper limit of liver enzymes is exceeded by more than three times.

Patients who already have liver illness or who are taking potentially hepatotoxic drugs at the same time should be treated with extra caution. Controlled data on the prevalence and risk factors for DILI linked to SGAs are scarce because these agents are relatively new. Marwick et al. reviewed 91 case reports/series and 10 group studies and discovered that the median for any abnormal liver function test was 32%, whereas the median for clinically significant liver enzyme increase was 4%.[36] The majority of these reactions occurred during the first six weeks, were self-limiting, and were asymptomatic. Chlorpromazine was the antipsychotic most frequently linked to acute liver injury.

Management

Opioids should always be started with lower doses and longer intervals between doses for patients with liver illness. Before giving greater dosages, determine the patient's tolerance. Since they are least impacted by persistent hemodynamic disruption, hydromorphone and fentanyl are the recommended medications for cirrhosis patients' pain management.[51] It is crucial to conduct close monitoring, evaluate those exhibiting declining liver function for indicators of opioid toxicity, and reduce dosages as needed.

It is important to consider the possibility that concurrently provided nonopioid drugs may impact opioid metabolism by stimulating or inhibiting the CYP family of enzymes, as all opioids undergo at least partial hepatic metabolism. Lastly, dose modifications based on glomerular filtration rate may be a wise strategy because the majority of patients with liver illness also have a higher chance of renal failure (hepatorenal syndrome), and renal impairment can affect opioid levels and raise risk of toxicity.[52]

Hepatic monitoring

Severity of hepatic disease

Although they are not diagnostically specific, elevated liver enzymes (AST and ALT) may indicate inflammatory hepatic illness. Of them, ALT is exclusive to the liver, and a normal ALT level 90% of the time rules out hepatic illness. A basic indicator of the degree and course of disease and damage is the AST/ALT ratio (also known as the De Ritis quotient); values less than 1 indicate mild liver injury, whereas values greater than 1-2 indicate serious inflammatory liver diseases.[47] A proven method for assessing the severity of liver illness is the Child-Turcotte-Pugh (CTP). Five criteria—serum albumin, serum bilirubin, encephalopathy, ascites, and prothrombin time—are used in the CTP scoring process to produce three phases, designated "A," "B," or "C." Five to six is considered stage A (well-compensated disease), seven to nine is considered stage B (significantly compromised functionality), and ten to fifteen is considered stage C (decompensated liver disease).[47]

Hepatic monitoring preferences before initiating Antipsychotics

Before initiating any psychiatric medication, liver function testing is not required. Measuring baseline hepatic function is crucial for adjusting dosages of several psychiatric drugs in patients with hepatic illness. A baseline liver function test is thought to be helpful when there are no previous studies. However, if there is no clinical indication of liver illness, treatment can start right away.[47]

Additionally, several psychiatric medications (such as valproate, carbamazepine, and disulfiram) are hepatotoxic and need to be monitored on a regular basis. If there are clinical signs of hepatic disease, such as lethargy, abdominal pain in the right upper quadrant, jaundice, etc., liver function tests should be performed for other medications.[47]

With minimal change in ALP levels, high serum ALT levels are the most prevalent form of hepatotoxicity, occurring in over 90% of cases. A cholestatic pattern can occasionally be observed when ALT levels are somewhat elevated and ALP levels are high. Together with these alterations, a high serum bilirubin level indicates significant liver injury and a worse prognosis. Psychotropic medications can occasionally cause steatosis or steatohepatitis, which is typically curable. The medication can be continued with routine monitoring at more frequent intervals if liver function tests reveal slight elevations in transaminase. When transaminase levels are three to four times the upper limit (i.e., 120–160), it is time to stop taking the offending medication.[47]

A dose reduction may be tried if continuing the medication is clinically indicated, although there is no proof that this approach is beneficial. It is best to avoid

this if there is an alternative treatment option available because it is likely to recur if there is a history of such hepatic inflammation with a medication. If liver functions are determined to be abnormal before to starting medication or if laboratory parameters alter while using psychiatric medicines, a hepatologist's opinion may be useful.

Hyperammonemia is linked to valproate therapy, particularly in patients with other risk factors including decreased carnitine levels. Regularly measuring serum ammonia levels prior to starting valproate medication is not required.[47]

Serum ammonia levels may be checked and valproate should be discontinued if a patient exhibits clinical symptoms of hyperammonemia, such as fatigue, lethargy, or disturbed mental status. Levocarnitine may occasionally be administered to treat hyperammonemia. Some patients may benefit from lowering their valproate dosage. Other causes of valproate-induced nonhepatic hyperammonemic encephalopathy (VNHE) include organic acidemias like methylmalonic acidemia, proprionic acidemia, and multiple carboxylase deficiency, as well as urea cycle disorders (late onset ornithine transcarbamylase deficiency). Malnutrition, chronic renal failure, ketogenic diet, strict vegetarianism, and concurrent use of certain antiepileptic medications that can lower carnitine levels (such as topiramate, phenytoin, carbamazepine, and phenobarbitone) are risk factors for secondary carnitine deficiency and VNHE.[47]

Drugs that escape hepatic metabolism

Clinical considerations for patients with hepatic disorders will benefit from an understanding of the medications that do not undergo hepatic metabolism. (Lithium, acamprostate, gabapentin)[51] Some medications are primarily eliminated by the kidneys and are not digested at all by the liver. Certain additional medications (Lorazepam, oxazepam, lamotrigine, levetiracetam) are only weakly metabolized by the liver; that is, only phase 2 conjugation reactions, which are comparatively preserved in hepatic cirrhosis, occur instead of phase 1 oxidation reactions, which are mediated by the cytochrome P450 system. Choosing a psychotropic and its dosage also depends on how much of the drug is processed by the liver compared to how much is eliminated unaltered (e.g. paliperidone and milnacipran).[47]

Due to decreased hepatic production of creatine, people with cirrhosis are known to have lower glomerular filtration rates and lower creatinine levels. Consequently, drugs like lithium that have a limited therapeutic index and are primarily eliminated via the kidneys should be administered cautiously in cirrhosis patients. Additionally, serum creatinine levels tend to overstate glomerular filtration rates in patients with cirrhosis and are not a reliable indicator of them.

sComparably, acamprosate is thought to be safe in cases of liver illness because it is not metabolized by the liver; nevertheless, its safety in patients with Child-Pugh class C cirrhosis has not been proven. Some pharmaceuticals, such as gabapentin and pregabalin, should be the first choice if clinically required because they don't require dose modifications in cirrhosis.

Preferable to medications involving cytochrome P450 metabolism are those that are only little metabolized and only go through conjugation reactions (e.g. lorazepam over diazepam for alcohol withdrawal in alcoholic liver illness). However, advanced liver diseases like cirrhosis are known to also affect conjugation reactions. As a result, it is recommended to modify dosages appropriately in cirrhosis patients. In addition to monitoring for symptoms of toxicity, a standard approach is to administer 50% of the regular dose to Child-Pugh class A patients and 25% to Child-Pugh class B patients.[54] These drugs should only be recommended for people with Child-Pugh class C patients if there is clinical safety data available.

CONCLUSION

Patients with liver diseases require customized psychopharmacology, depending on the severity of the underlying medical illness and the type of psychotropic medication used. Psychotropic medications that prevent or barely undergo hepatic metabolism are better for people with liver disease. Since there may not be enough safety data, care must be taken when providing any psychiatric medication to patients with severe liver illness. Preferring hepatic metabolism escaping drug may prevent further damage to liver Hepatic review refrences.

REFERENCES

1. Aithal GP, Watkins PB, Andrade RJ et al (2011) Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther, 89: 806–815.
2. Schuster D, Laggner C, Langer T. Why drugs fail--a study on side effects in new chemical entities. Curr Pharm Des., 2005; 11: 3545-3559.
3. Selim K, Kaplowitz N. Hepatotoxicity of psychotropic drugs. Hepatology, 1999; 29: 1347-1351.
4. DeSanty KP, Amabile CM. Antidepressant-induced liver injury. Ann Pharmacother, 2007; 41: 1201-1211.
5. Biour M, Salem CB, Chazouillères O, Grangé J-D, Serfati L, Poupon R. Hépatotoxicité des médicaments 14e mise à jour du fichier bibliographique des atteintes hépatiques et des médicaments responsables. Gastroentérologie Clinique et Biologique, 2004; 28: 720-59.
6. Vuppalanchi R, Hayashi PH, Chalasani N, Fontana RJ, Bonkovsky H, Saxena R, Kleiner D, Hoofnagle JH. Duloxetine hepatotoxicity: a case-series from the drug-induced liver injury network. Aliment Pharmacol Ther, 2010; 32: 1174-1183.

7. Gahr M, Freudenmann RW, Connemann BJ, Hiemke C, Schönfeldt-Lecuona C. Agomelatine and hepatotoxicity: implications of cumulated data derived from spontaneous reports of adverse drug reactions. Pharmacopsychiatry, 2013; 46: 214-220.
8. Telles-Correia D, Barbosa A, Cortez-Pinto H, Campos C, Rocha NB, Machado S. Psychotropic drugs and liver disease: a critical review of pharmacokinetics and liver toxicity. World journal of gastrointestinal pharmacology and therapeutics, 2017 Feb 2; 8(1): 26.
9. Gunther M, Dopheide JA. Antipsychotic safety in liver disease: a narrative review and practical guide for the clinician. Journal of the Academy of Consultation-Liaison Psychiatry, 2023 Jan 1; 64(1): 73-82.
10. Fan Y, Zhao H, Xie W. [Interpretation of the guidelines for the diagnosis and treatment of drug-induced liver injury]. Zhong Hua Quan Ke Yi Shi Za Zhi., 2016; 15(6): 416-420. Chinese.
11. Urichuk L, Prior TI, Dursun S, Baker G. Metabolism of atypical antipsychotics: involvement of cytochrome p 450 enzymes and relevance for drug-drug interactions. Curr Drug Metab., 2008; 9(5): 410-418.
12. Kaplowitz N, Aw TY, Simon FR, Stolz A. Drug-induced hepatotoxicity. Ann Intern Med., 1986; 104(6): 826-839.
13. Verma S, Kaplowitz N. Diagnosis, management and prevention of drug-induced liver injury. Gut., 2009; 58(11): 1555-1564.
14. DE Hert M, Schreurs V, Vancampfort D, VAN Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry, 2009; 8(1): 15-22.
15. Douros A, Bronder E, Andersohn F, Klimpel A, Thomae M, Sarganas G, et al. Drug-induced liver injury: results from the hospital-based Berlin Case-Control Surveillance Study. Br J Clin Pharmacol. 2015; 79(6): 988-999.
16. Hummer M, Kurz M, Kurzthaler I, Oberbauer H, Miller C, Fleischhacker WW. Hepatotoxicity of clozapine. J Clin Psychopharmacol. 1997; 17(4): 314-317.
17. Atasoy N, Erdogan A, Yalug I, Ozturk U, Konuk N, Atik L, et al. A review of liver function tests during treatment with atypical antipsychotic drugs: a chart review study. Prog Neuropsychopharmacol Biol Psychiatry, 2007; 31(6): 1255-1260.
18. Pae CU, Lim HK, Kim TS, Kim JJ, Lee CU, Lee SJ, et al. Naturalistic observation on the hepatic enzyme changes in patients treated with either risperidone or olanzapine alone. Int Clin Psychopharmacol, 2005; 20(3): 173-176.
19. Slim M, Medina-Caliz I, Gonzalez-Jimenez A, Cabello MR, Mayoral-Cleries F, Lucena MI, et al. Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future Directions. Drug Saf., 2016; 39(10): 925-943.
20. Sydney A Lefay, Antipsychotics safety in Liver disease, psychopharmacology institute, 2023.
21. Hughes E, Bassi S, Gilbody S, Bland M, Martin F Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness:A systematic review and meta-analysis Lancet Psychiatry, 2016; 3: 40-8.
22. Hsu JH, Chien IC, Lin CH, Chou YJ, Chou P Increased risk of chronic liver disease in patients with schizophrenia:A population-based cohort study Psychosomatics, 2014; 55(163): 71.
23. Hsu JH, Chien IC, Lin CH Increased risk of chronic liver disease in patients with bipolar disorder: A population-based study Gen Hosp Psychiatry, 2016; 42(54): 9.
24. McIntyre RS, Soczynska JK, Beyer JL, Woldeyohannes HO, Law CW, Miranda A, et al. Medical comorbidity in bipolar disorder: Re-prioritizing unmet needs Curr Opin Psychiatry, 2007; 20: 406-16.
25. Choi JM, Chung GE, Kang SJ, Kwak MS, Yang JI, Park B, et al. Association between anxiety and depression and nonalcoholic fatty liver disease Front Med (Lausanne), 2020; 7: 585618.
26. Weinstein AA, Kallman Price J, Stepanova M, Poms LW, Fang Y, Moon J, et al. Depression in patients with nonalcoholic fatty liver disease and chronic viral hepatitis B and C Psychosomatics, 2011; 52: 127-32.
27. Elwing JE, Lustman PJ, Wang HL, Clouse RE Depression, anxiety, and nonalcoholic steatohepatitis Psychosom Med., 2006; 68: 563-9.
28. Fontana RJ. Acute liver failure due to drugs. Semin Liver Dis., 2008; 28(2): 175–87.
29. Raschi E, De Ponti F. Drug- and herb-induced liver injury: progress, current challenges and emerging signals of post-marketing risk. World J Hepatol., 2015; 7(13): 1761–71.
30. Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med., 2016; 14: 10.
31. Todorović Vukotić N, et al. Antidepressants- and antipsychotics-induced hepatotoxicity. Arch Toxicol., 2021; 95(3): 767–89.
32. Gaertner I, et al. Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7,263 treatment courses. J Clin Psychopharmacol., 2001; 21(2): 215–22.
33. Mouradian-Stamatiadis L, et al. Liver function tests during treatment with antipsychotic drugs: a case series of 23 patients. Prog Neuropsychopharmacol Biol Psychiatry, 2002; 26(7–8): 1409–11.
34. Garcia-Unzueta MT, et al. Alterations of liver function test in patients treated with antipsychotics. J Clin Lab Anal, 2003; 17(6): 216–8.
35. Ozcanli T, et al. Severe liver enzyme elevations after three years of olanzapine treatment: a case report and review of olanzapine associated hepatotoxicity.

Prog Neuropsychopharmacol Biol Psychiatry, 2006; 30(6): 1163–6.
36. Marwick KF, Taylor M, Walker SW. Antipsychotics and abnormal liver function tests: systematic review. Clin Neuropharmacol., 2012; 35(5): 244–53.
37. Chinese Society of Hepatology, CMA. [Guidelines for the management of drug-induced liver injury]. Lin Chuang Gan Dan Bing Za Zhi., 2015; 31(11): 1752-1769.
38. Furge LL, Guengerich FP (2006) Cytochrome P450 enzymes in drug metabolism and chemical toxicology: an introduction. Biochem Mol Biol Educ., 34: 66–74.
39. Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther., 138: 103–141.
40. Yu K, Geng X, Chen M et al (2014) High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury. Drug Metab Dispos., 42: 744–750.
41. Mauri MC, Fiorentini A, Paletta S, Altamura AC (2014) Pharmacokinetics of antidepressants in patients with hepatic impairment. Clin Pharmacokinet, 53: 1069–1081.
42. Mauri MC, Paletta S, Di Pace C et al (2018) Clinical pharmacokinetics of atypical antipsychotics: an update. Clin Pharmacokinet, 57: 1493–1528.
43. Javaid JI (1994) Clinical pharmacokinetics of antipsychotics. J Clin Pharmacol, 34: 286–295.
44. Preskorn S, Werder S (2006) Detrimental antidepressant drug-drug interactions: are they clinically relevant? Neuropsychopharmacology, 31: 1605–1612.
45. Bleakley S (2016) Antidepressant drug interactions: Evidence and clinical significance. Prog Neurol Psychiatry, 20: 21–27.
46. Hrycay EG, Bandiera SM (2015) Involvement of cytochrome P450 in reactive oxygen species formation and cancer. Adv Pharmacol, 74: 35–84.
47. Menon V, Ransing R, Praharaj SK. Management of psychiatric disorders in patients with hepatic and gastrointestinal diseases. Indian Journal of Psychiatry, 2022 Mar 1; 64(Suppl 2): S379-93.
48. Carvalhana S, Oliveira A, Ferreira P, Resende M, Perdigoto R, Barroso E Acute liver failure due to trazodone and diazepam GE Port J Gastroenterol, 2017; 24: 40-2.
49. Bach N, Thung SN, Schaffner F, Tobias H Exaggerated cholestasis and hepatic fibrosis following simultaneous administration of chlorpromazine and sodium valproate Dig Dis Sci., 1989; 34: 1303-7.
50. Ahmed A Hepatitis and phenothiazines J Indian Med Assoc., 1972; 58: 300.
51. Jacobi J, Fraser GL, Coursin DB, Riker RR, Fontaine D, Wittbrodt ET, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult Crit Care Med., 2002; 30: 119-41.
52. Chandok N, Watt KD Pain management in the cirrhotic patient: The clinical challenge Mayo Clin Proc., 2010; 85: 451-8.
53. Andrade C Drugs that escape hepatic metabolism J Clin Psychiatry, 2012; 73: e889-90.
54. Delcò F, Tchambaz L, Schlienger R, Drewe J, Krähenbühl S Dose adjustment in patients with liver disease Drug Saf., 2005; 28: 529-45.